<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">Adv Biomed Res</journal-id><journal-id journal-id-type="publisher-id">ABR</journal-id><journal-title-group><journal-title>Advanced Biomedical Research</journal-title></journal-title-group><issn pub-type="ppub">2277-9175</issn><issn pub-type="epub">2277-9175</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25161987</article-id><article-id pub-id-type="pmc">4139977</article-id><article-id pub-id-type="publisher-id">ABR-3-140</article-id><article-id pub-id-type="doi">10.4103/2277-9175.135157</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shavakhi</surname><given-names>Ahmad</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Minakari</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Farzamnia</surname><given-names>Somaye</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Peykar</surname><given-names>Mohammad Saleh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Taghipour</surname><given-names>Golshan</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Tayebi</surname><given-names>Azadeh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Hashemi</surname><given-names>Huriyeh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Shavakhi</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib></contrib-group><aff id="aff1">Department of Internal Medicine, Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Medical Students&#x02019; Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Somaye Farzamnia, Department of Internal Medicine, Isfahan University of Medical Sciences, Hezar Jarib Street, Isfahan, Post Code: 81746-73461, Iran. E-mail: <email xlink:href="dr.farzamnia@yahoo.com">dr.farzamnia@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>25</day><month>6</month><year>2014</year></pub-date><volume>3</volume><elocation-id>140</elocation-id><history><date date-type="received"><day>02</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>07</day><month>5</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2014 Shavakhi.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Evidence has shown beneficial effects of probiotics in the treatment of irritable bowel syndrome (IBS); however, there is still a lack of data in this regard. We evaluated the efficacy of a multi-strain probiotic compound on IBS symptoms and quality-of-life (QOL).</p></sec><sec id="st2"><title>Materials and Methods:</title><p>Adult IBS patients (<italic>n</italic> = 132) were randomized to receive a probiotic compound containing seven bacteria species including <italic>Lactobacillus</italic> strains, <italic>Bifidobacterium strains</italic> and <italic>Streptococcus thermophiles</italic> or similar placebo, twice daily after a meal for 14 consecutive days. Improvement of IBS symptoms was assessed in categories of abdominal pain and distension and improvement of bowel habit. Improvement in patients QOL was assessed by the IBS-QOL instrument. Patients were evaluated for symptoms and QOL at baseline and then 1 month after completion of the treatment.</p></sec><sec id="st3"><title>Results:</title><p>After treatment, there was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (<italic>P</italic>&#x0003c;0.001), but there was no difference between the two groups in this regard (<italic>P</italic>&#x0003e;0.05). Improvement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (<italic>P</italic> = 0.910). There was no significant difference between the two groups in QOL after the treatment (<italic>P</italic> &#x0003e;0.05).</p></sec><sec id="st4"><title>Conclusions:</title><p>We found no beneficial effects over placebo for a 2-week treatment with the above mentioned multi-strain probiotic compound in the treatment of IBS. Further, trials are yet required before a clear conclusion in this regards.</p></sec></abstract><kwd-group><kwd>Irritable bowel syndrome</kwd><kwd>probiotics</kwd><kwd>therapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Irritable bowel syndrome (IBS) is the most common functional bowel disorder characterized by abdominal pain/discomfort accompanying with disturbed bowel habits. It is estimated that 3-15% of the general population have IBS world-wide, modestly more prevalent in women than in men.[<xref rid="ref1" ref-type="bibr">1</xref>] IBS possesses a chronic nature and affects patients physically, psychologically and economically and therefore, it is associated with impaired quality-of-life (QOL) and causes a major economic burden.[<xref rid="ref2" ref-type="bibr">2</xref>]</p><p>The pathophysiology of IBS is still not completely understood. Studies have shown that the etiology is most likely multifactorial and abnormal brain-gut interaction, food intolerance; altered microflora, post-infectious or inflammatory changes and genetic and psychological factors contribute to the pathogenesis of IBS.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] Heterogeneous pathophysiology and nature of IBS has a substantial impact on the efficacy of therapies for IBS. Only few therapies have been found to be effective in IBS treatment and treatments are not satisfactory in about half of the patients.[<xref rid="ref5" ref-type="bibr">5</xref>]</p><p>The role of altered gut microbiota in the pathogenesis of IBS is highlighted by evidences showing changes in fecal and mucosa associated microflora, post-infectious IBS phenomenon and the link with intestinal bacterial overgrowth and dysregulation of mucosal immune system. Therefore, investigators have tried to see the effects of alterations in the intestinal microflora on IBS symptoms.[<xref rid="ref6" ref-type="bibr">6</xref>] In this regard, the role of probiotics for intestinal functions and altered bowel microbiota, found in patients with IBS, has drawn attention toward these agents. Previous studies have shown beneficial effects of probiotics in the treatment of IBS and their safety has also contributed in to their popularity.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] However, the benefits are likely to be strain-specific[<xref rid="ref10" ref-type="bibr">10</xref>] and <italic>Bifidobacterium infantis</italic> has resulted in significant improvement in almost all IBS symptoms.[<xref rid="ref9" ref-type="bibr">9</xref>]</p><p>Based on some evidence, a mixture of probiotics that contains several species of bacteria could be more effective than a single species of bacteria in the treatment of some gastrointestinal diseases. It is assumed that multi-strain probiotics have synergistic effects that increase their effectiveness.[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref>] However, whether a probiotic mixture is more effective than a single agent in treatment of IBS is remained un-answered yet. Another remained concern is the world-wide generalizability of current studies results. Almost all clinical studies with microbial therapies are carried out with people from developed countries.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] Since, there is a variety in gut flora between different world's regions[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] the efficacy of probiotics may be affected by different ethnic groups of patients from different countries. There is no published report about probiotics efficacy on IBS treatment in Iran yet. Moreover, most of the previous studies are limited by small sample size.[<xref rid="ref15" ref-type="bibr">15</xref>] Considering the above mentioned questions and lack of qualified studies, the purpose of our study was to evaluate the efficacy of a multi-strain probiotic compound, Balance<sup>&#x000ae;</sup> (Protexin Co., Somerset, UK), in the treatment of Iranian IBS patients. Balance<sup>&#x000ae;</sup> contains seven species of bacteria including <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> species that separately have been shown helpful for treatment of IBS.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref16" ref-type="bibr">16</xref>] We hypothesized that this probiotic compound would decrease symptoms of IBS and increase the QOL.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Patients and setting</title><p>This randomized placebo-controlled triple-blinded study was conducted on adult patients with IBS referred to gastroenterology clinics of Alzahra University Hospital in Isfahan City (central Iran). IBS was diagnosed by a single gastroenterologist according to the Rome II criteria (reference is needed). Patients with symptoms presented at least for 2 days/week in the preceding 2 weeks were included. Those with any infectious diseases before or during the study that need antibiotic therapy, immune-deficient disease, history of surgery on the gastrointestinal tract and history of using antibiotics or probiotics within 4 weeks before the study were not included. Considering type I error = 0.05, study power = 0.8 and expecting 10 point increase in the QOL score,[<xref rid="ref17" ref-type="bibr">17</xref>] the study sample size was calculated as 66 cases per group. The study was approved by the Ethics Committee of Isfahan University of Medical Sciences and registered in the U.S. National Institutes of Health Protocol Registration System (available at clinicaltrials.gov NCT01837472). Informed consent was obtained from all patients after full explanation of the study aim and protocol.</p></sec><sec id="sec2-2"><title>Intervention</title><p>Patients were randomized into probiotic and placebo groups based on random table list. Patients in the probiotic group received the probiotic compound Balance<sup>&#x000ae;</sup> (Protexin Co., Somerset, UK), twice daily after a meal for 14 consecutive days. Balance&#x000ae; capsules contain seven bacteria species including Lactobacillus strains (<italic>Lactobacillus casei</italic>, <italic>Lactobacillus rhamnosus</italic>, <italic>Lactobacillus acidophilus</italic> and <italic>Lactobacillus bulgaricus</italic>), <italic>Bifidobacterium strains</italic> (<italic>Bifidobacterium breve</italic> and <italic>Bifidobacterium longum</italic>) and <italic>Streptococcus thermophiles</italic>. Total viable count is 1 &#x000d7; 10<sup>8</sup> CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate and hydroxypropyl methyl cellulose. Those in the placebo group received placebo capsules with the same order as probiotic group. No other treatment was prescribed for patients during the study period.</p></sec><sec id="sec2-3"><title>Assessments</title><p>Primary outcome of this study was improvement of IBS symptoms that was assessed in categories of abdominal pain and distension (from 0: No symptom to 3: Severe symptom) and improvement of bowel habit (get worse, no change, get better). Secondary outcome was improvement in patients QOL that was assessed by applying the IBS-QOL instrument. The IBS-QOL is a reliable and valid instrument for the assessment of IBS patients&#x02019; QOL. It contains 34 items with 5-point response scale (1: No problem to 5: Extreme problem). The total score is converted into 0-100 points for better interpretation.[<xref rid="ref17" ref-type="bibr">17</xref>] The Persian version of the IBS-QOL with sufficient psychometric properties was used in this study.[<xref rid="ref18" ref-type="bibr">18</xref>] Patients were evaluated for symptoms and QOL at baseline and then 1 month after completion of the treatment.</p></sec><sec id="sec2-4"><title>Statistical analyses</title><p>This study was designed as a triple-blind study and attending physicians, patients, principal investigators as well as data analyzer were all unaware about the treatment arms and drug codes. A third colleague who coded the probiotic and placebo capsules clarified the codes after data analyses. Data were analyzed using the SPSS software for windows version 16.0. Quantitative data and qualitative data were compared between the two groups with independent sample <italic>t</italic>-test and Chi-square/Mann-Whitney U tests, respectively. Paired <italic>t</italic>-test and Wilcoxon test were applied to assess changes in QOL score and symptoms severity within each group, respectively. A <italic>P</italic> value of less than 0.05 was considered as indicating a statistical significant difference in all analyses.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>A total of 160 patients were evaluated during the study period. Twenty eight patients were not included owing to unwillingness to participate, receiving antibiotics or probiotics at the time of the study. Thus, 132 patients were randomized into the probiotic and placebo groups. Three patients from the placebo group did not come for follow-up evaluations, not due to drug side effects. Thus, 129 patients completed the trial; 66 patients in the probiotic and 63 ones in the placebo group. Mean age was 36.2 &#x000b1; 9.3 years and 85 (65.9%) cases were female. The two groups were similar regarding demographic and baseline clinical characteristics [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparison of the two groups with regards to demographic and baseline clinical characteristics</p></caption><graphic xlink:href="ABR-3-140-g001"/></table-wrap><p>After the treatment period, there was a significant decrease in abdominal pain severity in both the probiotic (<italic>P</italic> &#x0003c; 0.001) and the placebo (<italic>P</italic> = 0.001) groups. There was no difference between the two groups in this regard (<italic>P</italic> = 0.558). Furthermore, distension severity decreased significantly in both probiotic (<italic>P</italic> &#x0003c; 0.001) and the placebo (<italic>P</italic> &#x0003c; 0.001) groups, but no difference was observed between the two groups in this regard (<italic>P</italic> = 0.673). Improvement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (<italic>P</italic> = 0.910). With regard to QOL, an improvement was observed in the probiotic (<italic>P</italic> = 0.008), but not in the placebo group (<italic>P</italic> = 0.175); though, there was no significant difference between the two groups in this regard (<italic>P</italic> = 0.372), <xref ref-type="table" rid="T2">Table 2</xref>. Further analysis in each subgroup of bowel habit did not change these results.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparison of the two groups with regards to symptoms and quality-of-life after treatment</p></caption><graphic xlink:href="ABR-3-140-g002"/></table-wrap><p>In the probiotic group, three patients experienced mild abdominal pain and nausea at the beginning of therapy, which disappeared by continuing the drug. No specific side-effect was reported in the placebo group.</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>The aim of the present study was to evaluate the efficacy of a multi-strain probiotic compound, which contains seven species of bacteria including <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> species in the treatment of Iranian IBS patients. We found no beneficial effects for this probiotic compound over placebo in reliving IBS symptoms. Although there was a statistically significant improvement in QOL score in the probiotic group, this change was not clinically important, which might be due to short duration of the study.</p><p>Previous studies on the efficacy of multi-strain probiotic compounds in the treatment of IBS have provided different results. Two small studies by Kim <italic>et al</italic>. on a probiotic compound containing <italic>Bifidobacterium</italic>, <italic>Lactobacillus</italic> and <italic>Streptococcus</italic> salivarius species for 4-8 weeks found beneficial effects of these probiotics over placebo only for bloating and flatulence symptoms.[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref>] Ki Cha <italic>et al</italic>. have evaluated a probiotic mixture containing <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> and <italic>S. thermophilus</italic> for 8 weeks and found an overall response rate of 48% versus 12% with placebo; though, it had no significant effect on individual symptoms.[<xref rid="ref21" ref-type="bibr">21</xref>] The study by Williams <italic>et al</italic>. on a combination of <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> species also found greater improvement in IBS symptom severity and also in QOL compared with placebo over the 8-week intervention period.[<xref rid="ref22" ref-type="bibr">22</xref>] Two other studies by Kajander <italic>et al</italic>. showed that a probiotic mixture of <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> species for 5 months can stabilize the intestinal microbiota and alleviate IBS symptoms.[<xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref>] In contrast to these reports, the study by S&#x000f8;ndergaard on a probiotic fermented milk containing Lactobacillus and Bifidobacterium species has found no special effect over acidified milk for 8 weeks.[<xref rid="ref25" ref-type="bibr">25</xref>] A similar study by Simr&#x000e9;n <italic>et al</italic>. also found no positive effect of such treatment.[<xref rid="ref26" ref-type="bibr">26</xref>] Our study also found no beneficial effects of multi-strain probiotic over placebo in the treatment of IBS. According to systematic reviews and meta-analyses on this subject, there is a considerable heterogeneity among previous clinical trials regarding study design, which prevent a clear conclusion. Studies are different considering the duration of treatment (2 weeks to 5 months), outcome assessments and the type and amount (drug dose) of intervention. A publication bias toward positive results also should be considered.[<xref rid="ref9" ref-type="bibr">9</xref>] Future studies should follow Rome Committee recommendations for appropriate design of clinical trials in this field.[<xref rid="ref27" ref-type="bibr">27</xref>]</p><p>There are some limitations for this study. We assessed abdominal pain, the most important IBS symptom for patients as well as other symptoms with a Likert scale. This type of assessment is based on clinical importance of change; however, it might not detect small changes. Therefore, it is better for future studies to apply more comprehensive evaluation of symptoms.[<xref rid="ref28" ref-type="bibr">28</xref>] Furthermore, the IBS-QOL evaluates QOL of the patient in the preceding 30 days; thus, 1 month was not an appropriate interval for expecting change in QOL and the study needed longer follow-up for evaluation of changes in QOL.</p></sec><sec sec-type="conclusions" id="sec1-5"><title>CONCLUSIONS</title><p>We found no beneficial effects for a 2-weeks treatment with a multi-strain probiotic compound containing <italic>Lactobacillus</italic> and <italic>Bifidobacterium species</italic> over placebo in the treatment of Iranian IBS patients. Further trials with longer duration of treatment and follow-ups are yet required before a clear conclusion in this regards. Such research should also focus on the type, optimal dose of probiotics and the subgroups of patients who are likely to benefit the most.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>This study was supported by the Isfahan University of Medical Sciences. Authors are thankful to Dr. Ali Gholamrezaei for helping us in data analysis and editing this report.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Isfahan University of Medical Sciences.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremonini</surname><given-names>F</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Irritable bowel syndrome: Epidemiology, natural history, health care seeking and emerging risk factors</article-title><source>Gastroenterol Clin North Am</source><year>2005</year><volume>34</volume><fpage>189</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">15862929</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L</given-names></name></person-group><article-title>Review article: Epidemiology and quality of life in functional gastrointestinal disorders</article-title><source>Aliment Pharmacol Ther</source><year>2004</year><volume>20</volume><issue>Suppl 7</issue><fpage>31</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15521853</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Current and emerging therapies in irritable bowel syndrome: From pathophysiology to treatment</article-title><source>Trends Pharmacol Sci</source><year>2010</year><volume>31</volume><fpage>326</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">20554042</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Lasch</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name></person-group><article-title>Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2012</year><volume>303</volume><fpage>G775</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">22837345</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><collab>American College of Gastroenterology Task Force on Irritable Bowel Syndrome</collab><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>LJ</given-names></name><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Foxx-Orenstein</surname><given-names>AE</given-names></name><name><surname>Schiller</surname><given-names>LR</given-names></name><name><surname>Schoenfeld</surname><given-names>PS</given-names></name><etal/></person-group><article-title>An evidence-based position statement on the management of irritable bowel syndrome</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><issue>Suppl 1</issue><fpage>S1</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">19521341</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkes</surname><given-names>GC</given-names></name><name><surname>Brostoff</surname><given-names>J</given-names></name><name><surname>Whelan</surname><given-names>K</given-names></name><name><surname>Sanderson</surname><given-names>JD</given-names></name></person-group><article-title>Gastrointestinal microbiota in irritable bowel syndrome: Their role in its pathogenesis and treatment</article-title><source>Am J Gastroenterol</source><year>2008</year><volume>103</volume><fpage>1557</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">18513268</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moayyedi</surname><given-names>P</given-names></name><name><surname>Ford</surname><given-names>AC</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Cremonini</surname><given-names>F</given-names></name><name><surname>Foxx-Orenstein</surname><given-names>AE</given-names></name><name><surname>Brandt</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review</article-title><source>Gut</source><year>2010</year><volume>59</volume><fpage>325</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">19091823</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoveyda</surname><given-names>N</given-names></name><name><surname>Heneghan</surname><given-names>C</given-names></name><name><surname>Mahtani</surname><given-names>KR</given-names></name><name><surname>Perera</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>N</given-names></name><name><surname>Glasziou</surname><given-names>P</given-names></name></person-group><article-title>A systematic review and meta-analysis: Probiotics in the treatment of irritable bowel syndrome</article-title><source>BMC Gastroenterol</source><year>2009</year><volume>9</volume><fpage>15</fpage><pub-id pub-id-type="pmid">19220890</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>DM</given-names></name><name><surname>Moeller</surname><given-names>MJ</given-names></name><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Schoenfeld</surname><given-names>PS</given-names></name></person-group><article-title>The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><fpage>1033</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">19277023</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>K</given-names></name></person-group><article-title>Probiotics and prebiotics in the management of irritable bowel syndrome: A review of recent clinical trials and systematic reviews</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2011</year><volume>14</volume><fpage>581</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21892075</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>CM</given-names></name><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Rowland</surname><given-names>I</given-names></name></person-group><article-title>Health benefits of probiotics: Are mixtures more effective than single strains?</article-title><source>Eur J Nutr</source><year>2011</year><volume>50</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">21229254</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>CM</given-names></name><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Rowland</surname><given-names>I</given-names></name></person-group><article-title><italic>In vitro</italic> evaluation of single-and multi-strain probiotics: Inter-species inhibition between probiotic strains, and inhibition of pathogens</article-title><source>Anaerobe</source><year>2012</year><volume>18</volume><fpage>405</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">22677262</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghoshal</surname><given-names>UC</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Gwee</surname><given-names>KA</given-names></name></person-group><article-title>Bugs and irritable bowel syndrome: The good, the bad and the ugly</article-title><source>J Gastroenterol Hepatol</source><year>2010</year><volume>25</volume><fpage>244</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">20074148</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ursell</surname><given-names>LK</given-names></name><name><surname>Clemente</surname><given-names>JC</given-names></name><name><surname>Rideout</surname><given-names>JR</given-names></name><name><surname>Gevers</surname><given-names>D</given-names></name><name><surname>Caporaso</surname><given-names>JG</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name></person-group><article-title>The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites</article-title><source>J Allergy Clin Immunol</source><year>2012</year><volume>129</volume><fpage>1204</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22541361</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simr&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Barbara</surname><given-names>G</given-names></name><name><surname>Flint</surname><given-names>HJ</given-names></name><name><surname>Spiegel</surname><given-names>BM</given-names></name><name><surname>Spiller</surname><given-names>RC</given-names></name><name><surname>Vanner</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intestinal microbiota in functional bowel disorders: A Rome foundation report</article-title><source>Gut</source><year>2013</year><volume>62</volume><fpage>159</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">22730468</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>G</given-names></name><name><surname>Cryan</surname><given-names>JF</given-names></name><name><surname>Dinan</surname><given-names>TG</given-names></name><name><surname>Quigley</surname><given-names>EM</given-names></name></person-group><article-title>Review article: Probiotics for the treatment of irritable bowel syndrome: Focus on lactic acid bacteria</article-title><source>Aliment Pharmacol Ther</source><year>2012</year><volume>35</volume><fpage>403</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">22225517</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Frederick</surname><given-names>IO</given-names></name><name><surname>DiCesare</surname><given-names>J</given-names></name><name><surname>Puder</surname><given-names>KL</given-names></name></person-group><article-title>Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure</article-title><source>Dig Dis Sci</source><year>1998</year><volume>43</volume><fpage>400</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">9512138</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gholamrezaei</surname><given-names>A</given-names></name><name><surname>Zolfaghari</surname><given-names>B</given-names></name><name><surname>Farajzadegan</surname><given-names>Z</given-names></name><name><surname>Nemati</surname><given-names>K</given-names></name><name><surname>Daghaghzadeh</surname><given-names>H</given-names></name><name><surname>Tavakkoli</surname><given-names>H</given-names></name><etal/></person-group><article-title>Linguistic validation of the Irritable Bowel Syndrome-Quality of Life Questionnaire for Iranian patients</article-title><source>Acta Med Iran</source><year>2011</year><volume>49</volume><fpage>390</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21874644</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>McKinzie</surname><given-names>S</given-names></name><name><surname>Lempke</surname><given-names>MB</given-names></name><name><surname>Burton</surname><given-names>DD</given-names></name><name><surname>Thomforde</surname><given-names>GM</given-names></name><etal/></person-group><article-title>A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome</article-title><source>Aliment Pharmacol Ther</source><year>2003</year><volume>17</volume><fpage>895</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">12656692</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Vazquez</surname><given-names>Roque MI</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Stephens</surname><given-names>D</given-names></name><name><surname>Burton</surname><given-names>DD</given-names></name><name><surname>Baxter</surname><given-names>K</given-names></name><etal/></person-group><article-title>A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating</article-title><source>Neurogastroenterol Motil</source><year>2005</year><volume>17</volume><fpage>687</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">16185307</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ki</surname><given-names>Cha B</given-names></name><name><surname>Mun</surname><given-names>Jung S</given-names></name><name><surname>Hwan</surname><given-names>Choi C</given-names></name><name><surname>Song</surname><given-names>ID</given-names></name><name><surname>Woong</surname><given-names>Lee H</given-names></name><name><surname>Joon</surname><given-names>Kim H</given-names></name><etal/></person-group><article-title>The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial</article-title><source>J Clin Gastroenterol</source><year>2012</year><volume>46</volume><fpage>220</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22157240</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>EA</given-names></name><name><surname>Stimpson</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Plummer</surname><given-names>S</given-names></name><name><surname>Garaiova</surname><given-names>I</given-names></name><name><surname>Barker</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study</article-title><source>Aliment Pharmacol Ther</source><year>2009</year><volume>29</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">18785988</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajander</surname><given-names>K</given-names></name><name><surname>Hatakka</surname><given-names>K</given-names></name><name><surname>Poussa</surname><given-names>T</given-names></name><name><surname>F&#x000e4;rkkil&#x000e4;</surname><given-names>M</given-names></name><name><surname>Korpela</surname><given-names>R</given-names></name></person-group><article-title>A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>22</volume><fpage>387</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16128676</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajander</surname><given-names>K</given-names></name><name><surname>Myllyluoma</surname><given-names>E</given-names></name><name><surname>Rajili&#x00107;-Stojanovi&#x00107;</surname><given-names>M</given-names></name><name><surname>Kyr&#x000f6;npalo</surname><given-names>S</given-names></name><name><surname>Rasmussen</surname><given-names>M</given-names></name><name><surname>J&#x000e4;rvenp&#x000e4;&#x000e4;</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota</article-title><source>Aliment Pharmacol Ther</source><year>2008</year><volume>27</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">17919270</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;ndergaard</surname><given-names>B</given-names></name><name><surname>Olsson</surname><given-names>J</given-names></name><name><surname>Ohlson</surname><given-names>K</given-names></name><name><surname>Svensson</surname><given-names>U</given-names></name><name><surname>Bytzer</surname><given-names>P</given-names></name><name><surname>Ekesbo</surname><given-names>R</given-names></name></person-group><article-title>Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: A randomized, placebo-controlled trial</article-title><source>Scand J Gastroenterol</source><year>2011</year><volume>46</volume><fpage>663</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">21443416</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simr&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Ohman</surname><given-names>L</given-names></name><name><surname>Olsson</surname><given-names>J</given-names></name><name><surname>Svensson</surname><given-names>U</given-names></name><name><surname>Ohlson</surname><given-names>K</given-names></name><name><surname>Posserud</surname><given-names>I</given-names></name><etal/></person-group><article-title>Clinical trial: The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome-a randomized, double-blind, controlled study</article-title><source>Aliment Pharmacol Ther</source><year>2010</year><volume>31</volume><fpage>218</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">19863495</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><collab>Design of Treatment Trials Committee</collab><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>EJ</given-names></name><name><surname>Whitehead</surname><given-names>WE</given-names></name><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Matsueda</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><etal/></person-group><article-title>Design of treatment trials for functional gastrointestinal disorders</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1538</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16678567</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gholamrezaei</surname><given-names>A</given-names></name><name><surname>Nemati</surname><given-names>K</given-names></name><name><surname>Emami</surname><given-names>MH</given-names></name></person-group><article-title>Which end point is more comprehensive in reflecting changes in irritable bowel syndrome treatment trials?</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><fpage>2859</fpage><pub-id pub-id-type="pmid">19888249</pub-id></element-citation></ref></ref-list></back></article>